Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT by Böhm, Michael et al.
  
 
 
 
 
Böhm, M., Komajda, M., Borer, J. S., Ford, I. , Maack, C., Tavazzi, L., 
Moyne, A. and Swedberg, K. (2018) Duration of chronic heart failure 
affects outcomes with preserved effects of heart rate reduction with 
ivabradine: findings from SHIFT. European Journal of Heart Failure, 
20(2), pp. 373-381. (doi:10.1002/ejhf.1021) 
   
There may be differences between this version and the published 
version. You are advised to consult the publisher’s version if you wish 
to cite from it. 
 
This is the peer-reviewed version of the following article: Böhm, M., 
Komajda, M., Borer, J. S., Ford, I. , Maack, C., Tavazzi, L., Moyne, A. 
and Swedberg, K. (2018) Duration of chronic heart failure affects 
outcomes with preserved effects of heart rate reduction with ivabradine: 
findings from SHIFT. European Journal of Heart Failure, 20(2), pp. 
373-381, which has been published in final form at 10.1002/ejhf.1021. 
This article may be used for non-commercial purposes in accordance 
with Wiley Terms and Conditions for Self-Archiving. 
 
 
 
http://eprints.gla.ac.uk/150049/ 
     
 
 
 
 
 
 
Deposited on 18 October 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
1 
 
03.08.2017 
DURATION OF CHRONIC HEART FAILURE AFFECTS 
OUTCOMES WITH PRESERVED EFFECTS OF HEART RATE 
REDUCTION WITH IVABRADINE: FINDINGS FROM SHIFT 
 
 
Michael Böhm, MDa, Michel Komajda, MDb, Jeffrey S Borer, MDc, Ian Ford, PhDd, 
Christoph Maack, MDa,  Luigi Tavazzi, MDe, Aurélie Moyne, PhDf,  and Karl 
Swedberg, MDg on behalf of the SHIFT Investigators 
 
aUniversitätsklinikum des Saarlandes, Universität des Saarlandes, Klinik für Innere 
Medizin III, Homburg/Saar, Germany 
b Department of Cardiology, Université Pierre et Marie Curie Paris VI, La Pitié-
Salpêtrière Hospital, Paris, France  
c Howard Gilman and Schiavone Institutes, State University of New York Downstate 
Medical Center, Brooklyn and New York, NY, USA  
d Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK 
e Maria Cecilia Hospital—GVM Care and Research, Ettore Sansavini Health Science 
Foundation, Cotignola, Italy 
f Institut de Recherches Internationales Servier, Suresnes, France 
g Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University 
of Gothenburg, Göteborg, Sweden and National Heart and Lung Institute, Imperial 
College, London, UK 
 
 
 
Funding Sources: SHIFT was supported by Servier, France.  
 
 
Address for correspondence: 
Michael Böhm, MD 
Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III  
Kardiologie, Angiologie und Internistische Intensivmedizin  
Kirrberger Str. 1  
66421 Homburg/Saar 
Germany  
Tel.: (+49)-6841-16-15031 
Fax: (+49)-6841-16-15032 
E-mail: michael.boehm@uks.eu 
 
 
Word Count: 2672 
2 
 
ABSTRACT 
AIMS In heart failure (HF) with reduced ejection fraction and sinus rhythm, heart rate 
(HR) reduction with ivabradine reduces the composite of cardiovascular death and 
heart failure hospitalization. 
 
METHODS AND RESULTS It is unclear whether the duration of HF prior to therapy 
independently affects outcomes and whether it modifies the effect of HR reduction. In 
SHIFT, 6505 patients with chronic HF (LVEF ≤35%), in sinus rhythm, HR ≥70 bpm, 
treated with guideline-recommended therapies were randomized to placebo or 
ivabradine. We examined outcomes and the treatment effect of ivabradine in patients 
with different HF durations. Prior to randomization, 1416 (ivabradine) and 1459 
(placebo) patients had HF duration > 4 weeks - <1.5 years; 836 and 806 patients 1.5 
to <4 years, and 989 and 999 patients had HF duration 4 years or longer on 
ivabradine and placebo, respectively. Patients with longer duration were older (62.5 
years vs 59.0 years, p<0.0001), had greater severity (NYHA III/IV in 56% vs 44.9%, 
p<0.0001), more comorbidities (myocardial infarction: 62.9% vs 49.4%, p<0.0001; 
renal dysfunction: 31.5% vs 21.5%, p<0.0001; peripheral artery disease: 7% vs 4.8%, 
p<0.0001 compared with patients with a more recent diagnosis. After adjustments, 
longer HF duration was independently associated with poorer outcome. Effects of 
ivabradine were independent of HF duration.  
 
CONCLUSIONS Duration of HF predicts outcome independently of risk indicators 
like higher age, greater severity and more comorbidities. HR reduction with 
ivabradine improved outcomes independently of HF duration. Thus, HF treatments 
should be initiated early and HF chronicity is important to characterize HF 
populations in future trials.  
 
Clinical Trial Registration  
Effects of ivabradine on cardiovascular events in patients with moderate to severe 
chronic heart failure and left ventricular systolic dysfunction. A three-year randomised 
double-blind placebo-controlled international multi-centre study; ISRCTN70429960 
 
Key words: chronic heart failure – chronicity of heart failure - heart rate – 
comorbidities – age - ivabradine 
 
Running Title: Heart failure duration modifies outcomes in HFREF  
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INTRODUCTION 
Chronic heart failure (CHF) is a clinical syndrome frequently accompanied by  a high 
load of comorbidities and characterized by poor outcome despite optimal medical 
guideline-directed treatments (1). In stable heart failure (HF) with reduced ejection 
fraction (HFrEF), it is not known whether the duration from the time of onset of signs 
or symptoms until full treatment initiation has an effect on clinical outcomes. 
Interestingly, mortality rates are different between acute de novo and acutely 
decompensated CHF patients (2,3). Cardiac resynchronization therapy initiated early 
after emerging HF symptoms improved clinical outcomes more than applied later 
after development of clinical symptoms (4). In patients requiring mechanical 
circulatory support, outcome was better in acute or sub-acute HF than in patients with 
worsening of CHF and longstanding symptoms (5). Whether these associations apply 
also to patients with stable CHF of different chronicity is not well examined. High 
resting heart rates are related to poor outcome in HFrEF in the general population 
(6), in patients with high risk for vascular disease (7) and stable HF (8). Consistently, 
heart rate reduction in patients in sinus rhythm above a resting heart rate of 70 bpm 
reduced the composite of cardiovascular death and hospitalization for HF (9) and in a 
population ≥75 bpm all secondary endpoints including all-cause death and 
cardiovascular death (10). This study addresses the two objectives of whether the 
duration of HF symptoms influences outcomes and whether the treatment effect of 
heart rate reduction with ivabradine is modified by the duration of CHF.  
 
METHODS  
Study Design and Participants. The SHIFT study (Effects of ivabradine on 
cardiovascular events in patients with moderate to severe chronic heart failure and 
left ventricular systolic dysfunction. A three-year randomised double-blind placebo-
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controlled international multicentre study; SHIFT (ISRCTN70429960) was a 
randomised double-blind placebo-controlled clinical trial in patients with moderate to 
severe HF and left ventricular dysfunction (LVEF ≤ 35%) with the diagnoses of heart 
failure at least > 4 weeks before randomization. Patients had to be in sinus rhythm, 
age >18 years with a heart rate at rest ≥70 bpm at two consecutive visits. Patients 
were either assigned to ivabradine or placebo. Ivabradine was started at 5 mg bid 
and adjusted according to heart rate achieved to either 7.5 mg or 2.5 mg bid. SHIFT 
randomized patients on optimal guideline-directed medications at maximally tolerated 
doses for CHF including β-blockers. The design (5) and the main results (9,10) of the 
SHIFT trial have been published previously. The primary endpoint was a composite 
of cardiovascular death or hospital admissions for worsening of HF. All endpoints 
were adjudicated by an independent endpoint committee (9,10). The SHIFT study 
showed that heart rate reduction with ivabradine reduced the composite of 
cardiovascular death and HF hospitalization with the lowest event rates occurring 
when heart rate on achieved treatment was below 60 bpm (8).  
 
Follow-up and outcomes. The duration of HF symptoms was captured in the case 
report forms in each patient by the investigators. HF duration at baseline was 
separated into groups of practical time frames >4 weeks - <1.5 year (n=2875), 1.5-<4 
years (n = 1642) and ≥ 4 years (n=1988) which roughly represented tertiles of HFrEF 
durations. In these groups, baseline characteristics as well as accompanying 
treatments were reported. The eight most prominent comorbidities (chronic 
obstructive pulmonary disease (COPD), diabetes mellitus, anemia, stroke, impaired 
renal function (glomerular filtration rate ≤60 ml/min), myocardial infarction, 
hypertension and peripheral artery disease) were reported and evaluated herein. The 
composite primary endpoint consisting of cardiovascular death and hospitalization for 
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worsening of HF was explored according to duration of HF in patients on placebo or 
on ivabradine.  
 
Statistical analysis. Descriptive statistics are presented as means ±standard 
deviation (SD) for continuous variables, and as numbers and percentages for 
categorical variables. For baseline characteristics, the pooled placebo and ivabradine 
groups were divided into groups with different HF duration at baseline (<1.5 years, 
1.5-<4 years and ≥4 years). Baseline characteristics were compared between the 
duration of HF groups using a Kruskal–Wallis test for continuous variables and a chi-
square test for categorical variables. In addition, we present the distribution of the 
number of comorbidities in patients on each treatment arm according to duration of 
HF groups. The association between risk and disease duration was tested in a Cox 
proportional hazards model, with disease duration as a continuous variable (1, 2, 3, 5 
or 10-year increase), adjusted for prognostic factors at baseline (β-blocker intake at 
randomization, heart rate, NYHA class, LVEF, ischaemic aetiology, systolic blood 
pressure, and estimated glomerular filtration rate), and hazard ratios (HRs), 95% 
confidence intervals (CIs), and p-value were calculated. All time-to-first-event 
regression analyses were based on Cox proportional hazard models. Hazard ratios 
for ivabradine treatment relative to placebo were provided with 95% confidence 
intervals, and p-values calculated from the Wald statistics. The treatment effect of 
ivabradine vs placebo was estimated in the duration of HF groups separately, from a 
Cox model adjusted for prognostic factors at baseline (β-blocker intake at 
randomization, NYHA class (III or IV/II), left ventricular ejection fraction (LVEF), 
ischemic heart failure (yes/no), age, systolic blood pressure, heart rate at baseline 
and creatinine estimated glomerular filtration rate (eGFR)). Sensitivity analyses were 
also performed with other adjustments (age + comorbidities, cf. supplement tab1). P-
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values for interaction between randomized treatments and duration of HF groups 
were also provided by addition of treatment by subgroup interaction to the model. 
The outcomes analyzed were the primary endpoint (composite of cardiovascular 
death or hospital admission for worsening of HF) as well as all-cause mortality and 
HF mortality. Time-to-event curves for each treatment arm according to duration of 
HF groups were estimated using the Kaplan-Meier method. SAS version 9.2 was 
used for all statistical analyses.  
 
RESULTS  
Baseline characteristics. In SHIFT, 6558 patients were randomized into the 
treatment arms (3268 ivabradine, 3290 placebo). 6505 patients had available data on 
duration of heart failure. Baseline characteristics of all patients according to HF 
duration at baseline are depicted in Table 1. 2875 patients had a HF duration of > 4 
weeks - <1.5 years, 1642 patients of 1.5-<4 years and 1988 patients >4 years. 
Patients with longer HF duration tended to be older with a higher body mass index, a 
lower eGFR and a higher systolic and diastolic blood pressure. Moreover, they were 
more likely to have a previous myocardial infarction, diabetes, stroke or lower eGFR. 
There was also heterogeneity between the HF functional classes (NYHA), but all 
patients had similar treatment intensities with ACE-inhibitors, ARBs and 
mineralocorticoid antagonists, with a higher rate of device utilization in those with 
longer HF duration. Prevalence of beta blocker pre-treatment was similar, but there 
were more patients on higher doses with longer duration.  
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Comorbidities.  In order to investigate whether there is a  different prevalence of 
single comorbidities in the groups of duration of HF observed at baseline, we 
investigated the total comorbidity load (i.e. numbers of comorbidities) in these 3 
groups. Figure 1 shows the distribution of the number of comorbidities by HF duration 
in the SHIFT population. In the group of short HF duration, more patients had 0 or 1 
comorbidities compared to HF durations ≥1.5 years. In patients with a HF duration ≥4 
years, 3 or 4 comorbidities were more prominent than in those patients with a shorter 
HF duration.  
 
Outcomes. Figure 2 shows the effect of HF duration on the primary composite 
endpoint on placebo (A) or ivabradine (B). For the primary endpoint there was a 
significantly higher event rate, when patients had a longer duration compared to an 
intermediate or shorter HF duration irrespective of whether they were on ivabradine 
(Figure 2A) or on placebo (Figure 2B) (log rank p<0.0001). Similar results were 
observed for cardiovascular death regardless whether patients were on placebo 
(Figure 2C, log rank p<0.0001) or ivabradine (Figure 2D, log rank p<0.0001). Similar 
results were obtained for worsening of HF (log rank p<0.0001) for placebo (Figure 
2E) and ivabradine (Figure 2F). To account for the high variability of disease 
durations, the associations were also evaluated in a statistical model with HF 
duration in a continuous manner.  Figure 3 shows that with longer disease duration 
risk is higher.  The disease duration is a risk indicator for cardiovascular outcomes in 
the SHIFT population.  
 
The treatment effects of ivabradine according to HF duration are summarized in 
Figure 4. Presented hazard ratios with 95% confidence interval are adjusted for 
prognostic factors at baseline (β-blocker intake at randomization, NYHA class, LVEF, 
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ischemic heart failure, age, systolic blood pressure, heart rate at baseline and 
creatinine clearance). There was a significant reduction of the primary composite 
endpoint and hospitalization for the worsening of HF irrespective of HF duration. 
There was a nominal decrease of cardiovascular mortality and all-cause mortality, 
which was not statistically significant, but a 40% decrease of HF mortality was 
observed in the subgroup of patients with a HF duration >4 years. We performed the 
same analyses with other adjustments. The effects of treatment were not affected by 
comorbidities or risk indicators (Suppl. Table 1).  In order to exclude a threshold of 
HF duration for the effect of ivabradine, an adjusted cox model on prognostic factors 
for the primary endpoint  was performed on patients having an HF duration >= 
threshold value  which varied from 0.5 years to 8 years. There was no threshold 
detectable (Figure 5). There was no significant heterogeneity of the treatment effects 
of ivabradine between the HF duration groups or defined endpoints. Neither the 
effect of HF duration on outcomes nor the effects of treatment were affected by 
comorbidities or risk indicators (Suppl. Table 1). The drop in HR after up-titration of 
ivabradine at 28 days was similar between the groups (>4 weeks – 1.5 years: 16.6 + 
10.9 bpm; 1.5 - 4 years: 14.6 + 10.8 bpm; >4 years: 15.8 + 10.4 bpm). 
 
DISCUSSION 
We demonstrated in this post-hoc analysis from the SHIFT study that the duration of 
HF was associated with morbidity and mortality. Although higher chronicity of HF was 
accompanied by a higher prevalence of single cardiac and non-cardiac comorbidities 
and a higher cumulative load of comorbid conditions, poor outcome was independent 
of comorbidities and risk indicators. The treatment effect of heart rate lowering with 
ivabradine was maintained across all groups with different HF durations.  
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Herein, we report a remarkable increase of all cardiovascular outcomes according to 
the duration of HF independent of comorbidities and risk indicators. This is to the best 
of our knowledge the first study to explore the impact of HF duration on outcomes in 
stable CHF. These data are in line with several studies on acute HF showing that 
mortality is higher in acute on chronic HF decompensation rather than on de novo HF 
decompensation (2,3). Furthermore, patients receiving a mechanical circulatory 
support system earlier in the course or CHF provide better outcomes than those with 
longstanding CHF before implantation (5). Finally, in patients with a shorter duration 
of CHF, a lower rate of cardiovascular death and HF hospitalization was observed 
after CRT implantation than in patients with longstanding symptoms (4). Recently, the 
ASCEND-HF investigators reported that patients with longer duration of the heart 
failure syndrome presenting with acute decompensation, had a higher 180-day 
mortality (11). The hazard ratios were between 1.82-2.02 between 1-12 month and > 
60 months being quite similar between the groups indicating that there was no 
gradual worsening of outcomes. Similarly, patients with longer duration of heart 
failure appeared to be more difficult to stabilize reflected by more persistent dyspnea 
at 24 hours (11). Therefore, pathophysiological changes driven by acute 
decompensation might modify the risk-duration relationship in solely chronic heart 
failure described herein. 
 
CHF is a long-term condition accompanied by cardiovascular remodeling, which is 
progressive over time (12). Therefore, it is likely that progressive maladaptive cardiac 
remodeling involving cardiac hypertrophy, defects in calcium handling and β-
adrenergic signal transduction in response to neuroendocrine activation (13,14) are 
involved, inducing continuous deterioration of cardiac function. Finally, it is very likely 
that recovery in terms of adaptive deremodeling is impaired in long-standing heart 
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failure compared to individuals with a more recent onset contributing to poorer 
outcomes. Patients with longer HF duration also differ concerning their baseline 
characteristic. Patients with longer duration of symptoms were older and had more 
previous myocardial infarctions, diabetes, stroke, atrial fibrillation, renal failure, 
chronic obstructive pulmonary disease and peripheral artery disease.  The 
association of HF duration to outcome was robust to adjustment for comorbidities or 
risk indicators. Comorbidities were associated with higher hospitalizations and 
morbidity (15,16,17), which are in turn related to higher age (18). Therefore, ageing, 
comorbidities and factors directly acting on the pathophysiology of cardiac 
remodeling or impairing cardiac recovery in HF (12) might further contribute to higher 
event rates according to the chronicity of CHF. Finally, sub-clinical decompensations 
below the threshold for hospitalizations in the outpatient setting might also be 
predictive, if not mechanistically involved, in death and hospitalization as shown 
recently (19). Patients with no or a remote decompensation, although having a 
somewhat lower risk, had a 22% incidence of cardiovascular death or heart failure 
hospitalization at follow-up in PARADIGM indicating that despite stability over a 
longer period of time, novel therapies should be introduced (20). 
 
Heart rate predicts outcome in CHF (10) and heart rate reduction reduces 
cardiovascular outcomes as shown in the SHIFT trial (9). The effect of heart rate 
reduction with ivabradine was unchanged within the groups of different HF durations. 
Heart rate reduction with ivabradine reduces progressive remodeling of the left 
ventricle (21). Relative risk reduction in the different HF duration groups was similar. 
This implies that a higher absolute event rate reduction might be attained in higher 
risk groups with longer HF duration. Therefore, early introduction of heart failure 
therapies as well as timely introduction of cardiac resynchronization devices (4) or, in 
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most severe HF, mechanical support systems (5) could provide higher absolute event 
rate reductions. In addition, the present findings show that the risk increase by HF 
duration is independent, however, accompanied by increased comorbidity loads. In 
many of these comorbid conditions heart rate also predicts risk, although an effect of 
heart rate reduction as CHF has not been shown yet. However, recent findings 
suggest that the effects of ivabradine in single-comorbid conditions like impaired 
renal function (22), chronic obstructive pulmonary disease (23), ageing (24) or high 
cumulative comorbidity load (17) is maintained. An outcome predictor of HF is low 
systolic blood pressure (25), in particular in association with high heart rate (26). 
However, herein, blood pressure was not different in patients with longstanding HF 
duration compared with lower chronicity, indicating that the age-associated increase 
in blood pressure overrides the HF associated decreases in blood pressure. Since 
heart rate is also associated with outcomes in conditions which are prominent 
comorbidities in HF, like chronic obstructive pulmonary disease, critical care disease, 
cancer (27,28) and endothelial function (29), the unaffected efficacy of heart rate 
reduction is not surprising.  
 
These findings might have also implications for future trial designs. Since patients 
with long HF duration differ considerably from those with shorter duration of HF, it is 
surprising that this parameter is neither reported in baseline characteristics of HF 
trials nor is part of the randomization stratification. It could further be used to enrich 
heart failure populations towards higher event rates, although in the overall 
population this could limit the generalizability of trial results. Nevertheless, this 
parameter should be taken into consideration of defining heterogeneity of HF 
populations and for power calculations of future trials.  
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Some limitations of this analysis need to be acknowledged. This is a retrospective 
analysis and the treatment groups in the sub-groups of HF duration are not subject to 
randomization. Therefore, this analysis is, by nature, hypothesis-generating.  
 
CONCLUSIONS 
These results from the SHIFT study show that the duration of CHF independently 
predicts poor outcome in patients with long HF duration and might be related to 
longstanding remodeling and poorer capacity to recover and deremodeling of the 
failing heart. It is however, accompanied by higher age and a higher prevalence of 
non-cardiac and cardiac comorbidities in these patients. This concept is summarized 
in Figure 6. There is no signal of heterogeneity in the treatment effect of heart rate 
reduction with ivabradine linked to the HF disease duration. A medical history of 
longer HF duration is a risk indicator and should, therefore, be introduced into 
randomization strategies and risk evaluation of heart failure populations in future 
clinical trials. 
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LEGENDS TO FIGURES 
Figure 1  
Distribution of the number of comorbidities in patients on placebo (left) or ivabradine 
(right) according to duration of HF (<1.5 year, 1.5-<4 years, ≥4 years).  
The percentages (%) were calculated in each class of disease duration. 
The HF durations were for the comorbidity groups (mean ± SD): 0: 2.33 +/-3.37 years 
(n=685); 1: 2.95+/-3.83 years (n=1437); 2: 3.72+/-4.57 years (n=2008); 3: 3.87+/-4.2; 
>/=4: 4.17+/-4.38 (n=890). 
 
Figure 2  
Kaplan-Meier event curves for the primary endpoint (A,B), cardiovascular death (C,D) 
and hospitalization for worsening HF (E,F), patients on placebo (A,C,E) or ivabradine 
(B,C,D) according to duration of HF (<1.5 year, 1.5-<4 years, ≥4 years). Log rank p-
values are given. Numbers at risk are depicted below Kaplan-Meier events curves.  
 
Figure 3  
Effect of a 1, 2, 3, 5 and 10-year increase using time as a continuous variable for the 
primary endpoint, hospitalization for worsening HF (WHF), cardiovascular (CV) death 
and all-cause death. Hazard ratios (95% CI) from a Cox model adjusted for 
prognostic factors. 
 
Figure 4  
Effect of ivabradine treatment in different duration of HF. Hazard ratios for the 
primary endpoint, cardiovascular mortality, all-cause mortality and heart failure 
mortality according to the duration of HF (<1.5 year, 1.5-<4 years, ≥4 years).  
a 
Number of patients in the placebo group: <1.5 years, n=1459; 1.5 to <4 years, 
n=806 ; and ≥4 years, n=999. Number of patients in the ivabradine group: <1.5 years, 
n=1416; 1.5 to <4 years, n=836; and ≥ 4 years, n=989. %PY=annual incidence rate 
b
 Adjusted for prognostic factors (β-blocker intake at randomisation, NYHA (III or IV / 
II), LVEF (%), ischaemic HF (yes/no), age (years), systolic blood pressure (mmHg), 
heart rate (bpm), creatinine clearance). 
c   P-value for interaction between randomized treatment and HF duration group. 
d 
Composite of cardiovascular mortality and hospitalization for worsening HF. 
 
Figure 5 
Effect of ivabradine  treatment for the primary endpoint  from a Cox model adjusted 
for prognostic factors  according to HF disease duration. 
For each value of the threshold (from 0.5 to 8 years by a 0.5 year step), the model 
was performed on the patients having a HF disease duration >= threshold value. 
 
Figure 6 
Interaction of duration of heart failure with progressive maladaptive 
responses, impaired recovery and comorbidities and prognosis. 
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This figure shows the concept of the impact on progressive remodeling, 
impaired deremodeling and recovery increasing loads of comorbidities and 
maladaptive responses according to the duration of heart failure. Early 
treatment might significantly slow the course of deterioration with evidence 
based treatments including heart rate reduction.  
Arrows depict heart failure decompensation without optimal treatment (blue 
area) or optimal treatment (green area). Comorbidities (red graph) and 
maladaptive remodeling (red shaded area) progress over time. 
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Table 1 – Baseline demographics and clinical characteristics of the total 
SHIFT population according to Heart failure duration at baseline 
 
 Heart failure duration at baseline P value 
 ≥4 weeks to <1.5 years 
n=2875 
1.5 to <4 years 
n=1642 
≥4 years 
n=1988 
Disease duration     
Mean, years (SD) 0.60 ± 0.38 2.64 ± 0.71 8.40 ± 4.51  
Median, years (Q1; Q3) 0.52 (0.26; 0.88) 2.61 (2.03; 3.21) 7.09 (5.24; 10.13)  
Demographic characteristics     
Mean age, years 58.96 ± 11.88 60.45 ± 11.03 62.45 ± 10.60 <.0001 
Male, % 77 77 75 0.4879 
Body mass index, kg/m2 27.53 ± 5.02 28.27 ± 5.01 28.43 ± 5.09 <.0001 
Cardiac parameters     
Heart rate, bpm 80.21 ± 9.94 79.56 ± 9.28 79.70 ± 9.42 0.1392 
SBP, mmHg 121.05 ± 16.29 122.00 ± 15.65 122.27 ± 15.70 0.0092 
DBP, mmHg  75.42 ± 9.58 76.08 ± 9.29 75.67 ± 9.49 0.0498 
LVEF, % 29.07 ± 5.10 29.16 ± 5.13 28.77 ± 5.24 0.0463 
Medical history     
NYHA Class II, % 
NYHA Class III, % 
NYHA Class IV, % 
55,03 
43,58 
1.32 
43,91 
54,38 
1.71 
43,56 
54,18 
2.26 
<.0001 
Duration of CHF, years 0.6 2.64 8.4 <.0001 
Ischaemic HF, % 62.61 73.26 71.18 <.0001 
Myocardial infarction, % 49.36 60.66 62.93 <.0001 
Hypertention, % 59.86 71.62 71.28 <.0001 
Diabetes, % 27.79 31.12 33.65 <.0001 
Stroke, % 6.30 8,53 10.16 <.0001 
AF and, or flutter, % 7.03 8.65 8.95 0.0291 
Renal failure, % 4.97 7.31 7.90 <.0001 
eGFR <60ml/min, % 21.46 27.22 31.54 <.0001 
Chronic obstructive pulmonary disease, % 10.23 12.24 11.82 0.071 
Peripheral artery disease, % 4.83 7.73 6.99 0.0001 
Anemia, % 7.90 7.61 7.04 0.5401 
Treatment at randomization     
Beta-blockers, % 89.77 89.77 88.78 0.4882 
Beta-blockers dose ≥50% of target, % 51.30 58.82 59.47 <.0001 
Beta-blockers dose ≥100% of target, % 22.28 28.58 29.45 <.0001 
ACE inhibitor, % 77.84 79.42 79.18 0.3656 
ARB, % 13.88 13.52 15.39 0.2056 
ACE inhibitor and/or ARB, % 90.02 90.93 92.66 0.0064 
MRA, % 61.01 59.74 59.71 0.5753 
Diuretics, % 82.12 84.10 84.10 0.1044 
At least one device, % 2.61 3.17 5.89 <.0001 
Randomised to ivabradine, % 49.25 50.91 49.75 0.5598 
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